CN Patent

CN102391271A — 生产镇痛药的改进方法

Assigned to Johnson Matthey PLC · Expires 2012-03-28 · 14y expired

What this patent protects

生产镇痛药的改进方法。含有低于10ppm的α，β不饱和酮的改进的镇痛药盐酸羟吗啡酮，和含有这种盐酸羟吗啡酮的药物制剂。通过利用氢气，在特殊的酸性、溶剂系统和温度条件下，还原起始材料盐酸羟吗啡酮而制得这种盐酸羟吗啡酮。可以通过水合得到这种盐酸羟吗啡酮的特定多晶型物。

USPTO Abstract

生产镇痛药的改进方法。含有低于10ppm的α，β不饱和酮的改进的镇痛药盐酸羟吗啡酮，和含有这种盐酸羟吗啡酮的药物制剂。通过利用氢气，在特殊的酸性、溶剂系统和温度条件下，还原起始材料盐酸羟吗啡酮而制得这种盐酸羟吗啡酮。可以通过水合得到这种盐酸羟吗啡酮的特定多晶型物。

Drugs covered by this patent

oxymorphone-hydrochloride (OXYMORPHONE HYDROCHLORIDE)

Patent Metadata

Patent number: CN102391271A
Jurisdiction: CN
Classification: —
Expires: 2012-03-28
Drug substance claim: No
Drug product claim: No
Assignee: Johnson Matthey PLC
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.